RNAZライブシグナル | Getagraph.comで利益を最大化

Live Chart Being Loaded With Signals

Commentary (30 4月 2024 @ 01:40):

TransCode Therapeutics, Inc., a biopharmaceutical company, engages in the development and commercialization of drugs and diagnostics for treating and identifying metastatic disease...

Stats
本日の出来高	844 779
平均出来高	509 146
時価総額	4.06M
EPS	$0 ( 2024-03-29 )
次の収益日	( $0 ) 2024-05-20
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	0
ATR14	$0.00400 (0.65%)

Insider Trading

Date	Person	Action	Amount	type
2023-09-28	Fitzgerald Thomas A	Buy	49 350	Common Stock
2023-09-28	Dudley Robert Michael	Buy	98 000	Common Stock
2023-06-21	Dudley Robert Michael	Buy	12 000	Common Stock
2023-06-20	Dudley Robert Michael	Buy	6 607	Common Stock
2023-06-09	Dudley Robert Michael	Buy	19 000	Common Stock

INSIDER POWER
100.00
Last 36 transactions
Buy: 2 048 457 \| Sell: 1 170 653

ボリューム相関

長: 0.27 (neutral)

短: -0.32 (neutral)

Signal:(51.921) Neutral

TransCode Therapeutics, 相関

10 最も正の相関
APOP	0.933
MAGS	0.88
CMLF	0.856
RMRM	0.838

10 最も負の相関
MXIM	-0.807
MMAC	-0.805
WLTW	-0.805

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

TransCode Therapeutics, 相関 - 通貨/商品

-0.66
( moderate negative )

-0.05
( neutral )

0.00
( neutral )

-0.84
( strong negative )

0.50
( neutral )

TransCode Therapeutics, 財務諸表

Annual	2023
収益:	$0
総利益:	$-516 746 (0.00 %)
EPS:	$-103.61

FY	2023
収益:	$0
総利益:	$-516 746 (0.00 %)
EPS:	$-103.61

FY	2022
収益:	$0
総利益:	$-98 606.00 (0.00 %)
EPS:	$-2 165.71

FY	2021
収益:	$0.00
総利益:	$0.00 (0.00 %)
EPS:	$-1.133

Financial Reports:

No articles found.

TransCode Therapeutics,

TransCode Therapeutics, Inc., a biopharmaceutical company, engages in the development and commercialization of drugs and diagnostics for treating and identifying metastatic disease. Its lead therapeutic candidate, TTX-MC138, is a preclinical stage product for the treatment of metastatic cancer. The company's products in preclinical programs include TTX-siPDL1, an siRNA-based modulator of programmed death-ligand 1; TTX-siLIN28B, an siRNA-based inhibitor of RNA-binding protein LIN28B. Its cancer agnostic programs comprise TTX-RIGA, an RNAbased agonist of the RIG-I-driven immune response in the tumor microenvironment; TTX-CRISPR, a CRISPR/Cas9based therapy platform for the repair or elimination of cancer-causing genes inside tumor cells; and TTX-mRNA, an mRNA-based platform for the development of cancer vaccines meant to activate cytotoxic immune responses against tumor cells. The company was incorporated in 2016 and is based in Boston, Massachusetts.